The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis
- Equal contributors
1 Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain
2 Cardiology Division, Hospital Xeral-Calde, Lugo, Spain
3 Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain
4 Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain
5 Division of Rheumatology, Hospital Xeral-Calde, Lugo, Spain
6 Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IFIMAV, Santander, Spain
Arthritis Research & Therapy 2012, 14:R42 doi:10.1186/ar3755Published: 1 March 2012
Rheumatoid arthritis (RA) is an inflammatory disease associated with accelerated atherosclerosis and high risk of cardiovascular (CV) disease. Since genome-wide association studies demonstrated association between rs599839 polymorphism and coronary artery disease, in the present study we assessed the potential association of this polymorphism with endothelial dysfunction, an early step in atherogenesis.
A total of 128 RA patients without history of CV events were genotyped for rs599839 A/G polymorphism. The presence of endothelial dysfunction was assessed by brachial ultrasonography (brachial flow-mediated endothelium-dependent (FMD)).
Patients carrying the allele G exhibited more severe endothelial dysfunction (FMD%: 4.61 ± 3.94%) than those carrying the wild allele A (FMD%: 6.01 ± 5.15%) (P = 0.08). Adjustment for gender, age at the time of study, follow-up time and classic CV risk factors disclosed a significant association between the rs599839 polymorphism and FMD (G vs. A: P = 0.0062).
Our results confirm an association of the rs599839 polymorphism with endothelial dysfunction in RA.